Condition: Esophageal Cancer · Gastric Adenocarcinoma · HER2 Gene Mutation · Sponsor: Memorial Sloan Kettering Cancer Center
The purpose of this study to find out whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer.
This description comes directly from the study's public registry record.
Yelena Janjigian, MD · 646-888-4186 · janjigiy@mskcc.org
Samuel Cytryn, MD · cytryns@mskcc.org
Always discuss trial participation with your own doctor first.
| Massachusetts General Hospital (Data Collection Only) | Boston, Massachusetts, United States | Recruiting |
| Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) | Basking Ridge, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity) | Commack, New York, United States | Recruiting |
| Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Uniondale, New York, United States | Recruiting |
| University of Pennsylvania (Data Collection Only) | Philadelphia, Pennsylvania, United States | Recruiting |
| MD Anderson Cancer Center (Data Collection Only) | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06123338